Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.

Beer TM, Smith DC, Hussain A, Alonso M, Wang J, Giurescu M, Roth K, Wang Y.

Br J Cancer. 2012 Aug 21;107(5):808-13. doi: 10.1038/bjc.2012.339.

PMID:
22850553
2.

Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.

Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ.

Cancer. 2011 Jun 1;117(11):2419-25. doi: 10.1002/cncr.25810.

PMID:
24048789
3.

Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy.

Morrow PK, Divers S, Provencher L, Luoh SW, Petrella TM, Giurescu M, Schmelter T, Wang Y, Hortobagyi GN, Vahdat LT.

Breast Cancer Res Treat. 2010 Oct;123(3):837-42. doi: 10.1007/s10549-010-1102-x.

PMID:
20697802
4.

Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer.

Heigener DF, von Pawel J, Eschbach C, Brune A, Schmittel A, Schmelter T, Reck M, Fischer JR.

Lung Cancer. 2013 Jun;80(3):319-25. doi: 10.1016/j.lungcan.2013.02.007.

PMID:
23522488
5.

Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancer.

Gauler TC, Christoph DC, Fischer J, Frickhofen N, Huber R, Gonschorek C, Roth K, Giurescu M, Eberhardt WE.

Eur J Cancer. 2013 Jul;49(11):2461-8. doi: 10.1016/j.ejca.2013.03.029.

PMID:
23692812
6.

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.

Sridhar SS, Canil CM, Chi KN, Hotte SJ, Ernst S, Wang L, Chen EX, Juhasz A, Yen Y, Murray P, Zwiebel JA, Moore MJ.

Cancer Chemother Pharmacol. 2011 Apr;67(4):927-33. doi: 10.1007/s00280-010-1389-7.

PMID:
20602233
7.

Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.

Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1455-61. doi: 10.1007/s00280-011-1594-z. Erratum in: Cancer Chemother Pharmacol. 2011 Jun;67(6):1463.

PMID:
21365219
8.

Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).

Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD, Polee M, Gerritsen W, Dalesio O, de Wit R.

Eur J Cancer. 2012 Nov;48(16):2993-3000. doi: 10.1016/j.ejca.2012.05.014.

PMID:
22677260
9.

Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.

Fleming MT, Sonpavde G, Kolodziej M, Awasthi S, Hutson TE, Martincic D, Rastogi A, Rousey SR, Weinstein RE, Galsky MD, Berry WR, Wang Y, Boehm KA, Asmar L, Rauch MA, Beer TM.

Clin Genitourin Cancer. 2012 Mar;10(1):6-14. doi: 10.1016/j.clgc.2011.11.003.

PMID:
22340631
10.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x.

PMID:
22369348
11.

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, Hudes GR.

Eur J Cancer. 2012 Jan;48(1):85-93. doi: 10.1016/j.ejca.2011.10.014.

PMID:
22129890
12.

Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.

Schallier D, Decoster L, Braeckman J, Fontaine C, Degrève J.

Anticancer Res. 2012 Feb;32(2):633-41.

PMID:
22287756
13.

No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.

Hervonen P, Tulijoki T, Kellokumpu-Lehtinen P.

Anticancer Res. 2012 Aug;32(8):3305-9.

PMID:
22843906
14.

Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer.

Montanari M, Fabbri F, Rondini E, Frassineti GL, Mattioli R, Carloni S, Scarpi E, Zoli W, Amadori D, Cruciani G.

Tumori. 2012 Nov;98(6):696-701. doi: 10.1700/1217.13491.

PMID:
23389354
15.

Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.

Zhang HL, Ye DW, Yao XD, Dai B, Zhang SL, Shen YJ, Zhu Y, Zhang W.

Urol Int. 2007;79(4):307-11.

PMID:
18025847
16.

Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.

Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, Müller SC, Albers P, Gschwend J, Wirth M, Steiner U, Miller K, Heinrich E, Trojan L, Volkmer B, Honecker F, Bokemeyer C, Keck B, Otremba B, Ecstein-Fraisse E, Pfister D.

Eur Urol. 2013 Jun;63(6):977-82. doi: 10.1016/j.eururo.2012.08.058.

PMID:
23116658
17.

Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.

Mardjuadi F, Medioni J, Kerger J, D'Hondt L, Canon JL, Duck L, Musuamba F, Oudard S, Clausse M, Moxhon A, Machiels JP.

Cancer Chemother Pharmacol. 2012 Aug;70(2):293-303. doi: 10.1007/s00280-012-1914-y.

PMID:
22752248
18.

A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.

Morris MJ, Kelly WK, Slovin S, Ryan C, Eicher C, Heller G, Scher HI.

J Urol. 2007 Dec;178(6):2378-83; discussion 2383-4.

PMID:
17936848
19.

Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer.

Buch-Hansen TZ, Bentzen L, Hansen S, Hoeyer M, Jensen NV, Saxe C, Sengeloev L.

Cancer Chemother Pharmacol. 2010 Jul;66(2):295-301. doi: 10.1007/s00280-009-1163-x.

PMID:
19882157
20.

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ.

Cancer. 2007 Aug 1;110(3):556-63.

PMID:
17577218
Items per page

Supplemental Content

Support Center